Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Heparinized Saline Kit Market Growing Rapidly
March 1, 2004
- BUSINESS NEWS IN BRIEF
March 1, 2004
- WEBSITE NEWS
March 1, 2004
- Chugai Aims at Top in Priority Fields: Cancer, Nephropathy, Bone
March 1, 2004
- Taisho: Downward Revisions in FY2003 Business Forecast
March 1, 2004
- 1st 3 Qtrs Business Results
March 1, 2004
- 1st Qtrs Business Results
March 1, 2004
- Pfizer Japan to Build Up Ophthalmology Business in Japan
February 23, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 23, 2004
- Takeda's MRs Are Best to Solve Doctors' Problems: Moss Survey
February 23, 2004
- Efficiency of NHI Price System Increased: Dr Yazaki
February 23, 2004
- BUSINESS NEWS IN BRIEF
February 23, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
February 23, 2004
- 1st 3 Qtrs Business Results
February 23, 2004
- Chugai Enhancing R&D Efficiency via Information Sharing
February 23, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 23, 2004
- PRESS SEMINAR
February 23, 2004
- OTC NEWS IN BRIEF
February 23, 2004
- Schedule until Full Enactment of Amended PAL Explained
February 23, 2004
- Purchase Prices of Medical Materials Show Wide Variation
February 23, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…